Evidence map›Paper›PMID 23995537›Full record

ArticleCirculation2013

Purification of cardiomyocytes from differentiating pluripotent stem cells using molecular beacons that target cardiomyocyte-specific mRNA.

Kiwon Ban, Brian Wile, Sangsung Kim, Hun-Jun Park, Jaemin Byun, Kyu-Won Cho, Talib Saafir, Ming-Ke Song, Shan Ping Yu, Mary Wagner and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Circulation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 64 citations in OpenAlex.

  1. Enhancing Cardiomyocyte Purity through Lactate-Based Metabolic Selection.Tissue engineering and regenerative medicine · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Kiwon Ban *Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Brian Wile *Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA.
Sangsung KimDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Hun-Jun ParkDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Jaemin ByunDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Kyu-Won ChoDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Talib SaafirDepartment of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA.
Ming-Ke SongDepartment of Anesthesiology, Emory University School of Medicine, Atlanta, GA.
Shan Ping YuDepartment of Anesthesiology, Emory University School of Medicine, Atlanta, GA.
Mary WagnerDepartment of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA.
Gang BaoDepartment of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA.
Young-Sup YoonDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Emory University · USGeorgia Institute of Technology · USSeoul St. Mary's Hospital · KRCatholic University of Korea · KR

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Cell therapy for diabetic peripheral neurovascular complicationsDP3DK094346 · NIDDK · EMORY UNIVERSITY · PI CHENG, XIAODONG, YOON, YOUNG-SUP · 2011 to 2011
$6.1M
Excitation-contraction coupling in human ventricle developmentR01HL088488 · NHLBI · EMORY UNIVERSITY · PI WAGNER, MARY B · 2008 to 2012
$2.5M
NCATS NIH HHS UL1 TR000454NCRR NIH HHS UL1 RR025008NHLBI NIH HHS HHSN268201000043CNHLBI NIH HHS R01 HL088488NHLBI NIH HHS R01HL088488NIDDK NIH HHS DP3 DK094346NIDDK NIH HHS DP3DK094346
6 · The paper itself

Abstract

backgroundAlthough methods for generating cardiomyocytes from pluripotent stem cells have been reported, current methods produce heterogeneous mixtures of cardiomyocytes and noncardiomyocyte cells. Here, we report an entirely novel system in which pluripotent stem cell-derived cardiomyocytes are purified by cardiomyocyte-specific molecular beacons (MBs). MBs are nanoscale probes that emit a fluorescence signal when hybridized to target mRNAs. METHOD AND

resultsFive MBs targeting mRNAs of either cardiac troponin T or myosin heavy chain 6/7 were generated. Among 5 MBs, an MB that targeted myosin heavy chain 6/7 mRNA (MHC1-MB) identified up to 99% of HL-1 cardiomyocytes, a mouse cardiomyocyte cell line, but <3% of 4 noncardiomyocyte cell types in flow cytometry analysis, which indicates that MHC1-MB is specific for identifying cardiomyocytes. We delivered MHC1-MB into cardiomyogenically differentiated pluripotent stem cells through nucleofection. The detection rate of cardiomyocytes was similar to the percentages of cardiac troponin T- or cardiac troponin I-positive cardiomyocytes, which supports the specificity of MBs. Finally, MHC1-MB-positive cells were sorted by fluorescence-activated cell sorter from mouse and human pluripotent stem cell differentiating cultures, and ≈97% cells expressed cardiac troponin T or cardiac troponin I as determined by flow cytometry. These MB-based sorted cells maintained their cardiomyocyte characteristics, which was verified by spontaneous beating, electrophysiological studies, and expression of cardiac proteins. When transplanted in a myocardial infarction model, MB-based purified cardiomyocytes improved cardiac function and demonstrated significant engraftment for 4 weeks without forming tumors.

conclusionsWe developed a novel cardiomyocyte selection system that allows production of highly purified cardiomyocytes. These purified cardiomyocytes and this system can be valuable for cell therapy and drug discovery.

Indexed as

Action PotentialsAnimalsBiomarkersCell DifferentiationCell LineCells, CulturedCell TransplantationFlow CytometryHumansMiceMyocardial InfarctionMyocytes, CardiacMyosin Heavy ChainsNanotechnologyNucleic Acid ConformationPluripotent Stem CellsBiomarkersMyosin Heavy ChainsRNA, MessengerRNA ProbesTroponin ITroponin Tmyocytes, cardiacoligonucleotide probespluripotent stem cellsregeneration

Identifiers

PMID23995537
PMCPMC3878656
OpenAlexW1974998407

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.